NCT05745142 2024-08-05A Study to go Back Into Records and Observe How People With Metastatic Renal Cell Carcinoma (mRCC) Who Received a Medicine Called Sunitinib Responded to This Medicine.PfizerCompleted376 enrolled 17 charts
NCT04669366 2024-07-19Treatment Patterns With Targeted Therapies In Mrcc In Sweden - A Retrospective Analysis Of Data From National RegistriesPfizerCompleted1,205 enrolled 14 charts
NCT02282059 2024-06-20The Safety And Efficacy Of Sunitinib In Chinese Patients With Progressive Advanced Or Metastatic Well-Differentiated Unresectable Pancreatic Neuroendocrine TumorsPfizerCompleted100 enrolled 13 charts
NCT00716625 2023-05-03Special Investigation For Renal Cell Carcinoma (RCC) Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan)PfizerCompleted1,674 enrolled 17 charts
NCT04175262 2023-05-03Clinical Outcomes For Patients With Metastatic Renal Cell Carcinoma (mRCC) Who Received Sunitinib After 1st Line Immune-oncology (IO) TreatmentsPfizerCompleted102 enrolled 23 charts
NCT00716820 2023-04-06Special Investigation For Gist Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan).PfizerCompleted472 enrolled 19 charts
NCT04033991 2023-04-06Study of Patients With Metastatic and/or Advanced Renal Cell Carcinoma, Treated With Sunitinib/Axitinib.PfizerCompleted684 enrolled 20 charts
NCT04076787 2023-04-06Clinical Outcomes for Patients With Renal Cell Carcinoma Who Received First-Line SunitinibPfizerCompleted1,769 enrolled 12 charts
NCT04115189 2022-05-10A Retrospective Medical Record Review of First-Line Sunitinib Administration Schedules and Outcomes Among Patients With mRCC in Latin America (LA)PfizerCompleted57 enrolled 35 charts
NCT00444795 2017-02-01Post Marketing Surveillance Study To Observe Safety And Efficacy Of SutenePfizerCompleted520 enrolled 8 charts
NCT00684645 2012-08-21Non-Interventional Study (NIS) In Patients With Advanced And/Or Metastatic Renal Cell Carcinoma (mRCC) Treated With SUTENT®PfizerCompleted186 enrolled 25 charts